| Market Capitalization (Millions $) |
78 |
| Shares
Outstanding (Millions) |
62 |
| Employees |
224 |
| Revenues (TTM) (Millions $) |
145 |
| Net Income (TTM) (Millions $) |
-53 |
| Cash Flow (TTM) (Millions $) |
-37 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
IGM Biosciences Inc. is a biotechnology company headquartered in Mountain View, California, that develops engineered antibodies for the treatment of cancer and other diseases. The companyes proprietary platform, called IgM Discovery Engine, allows for the creation of IgM antibodies that are designed to have improved pharmacokinetics, increased potency, and prolonged serum half-life.
The company was founded in 2010 by Dr. Fred Schwarzenbach, Dr. Shane Olwill, and Dr. John Eaton, and went public in 2019. IGM Biosciences is led by a team of experienced executives and scientists who have extensive experience in the development and commercialization of biological products.
IGMes pipeline includes several compounds that are currently in preclinical and clinical development. Its lead candidate, IGM-2323, is being evaluated in a Phase 1 trial for the treatment of relapsed or refractory B-cell Non-Hodgkines Lymphoma (NHL) and other B-cell malignancies. IGM-2323 is designed to target CD20, a protein that is overexpressed on the surface of B-cells in NHL.
The companyes other preclinical programs include IGM-8444, a compound that targets Death Receptor 5 (DR5) to induce apoptosis in cancer cells, and IGM-7354, a compound that targets the immune checkpoint molecule PD-L
IGM Biosciences has collaborations with several pharmaceutical companies, including AbbVie, Merck, and Genentech. The company has also received grants from the National Cancer Institute and the Cancer Prevention and Research Institute of Texas.
In summary, IGM Biosciences Inc. is a biotechnology company focused on developing engineered antibodies for the treatment of cancer and other diseases. The companyes proprietary platform, the IgM Discovery Engine, enables the creation of IgM antibodies with improved pharmacokinetics, increased potency, and prolonged serum half-life. IGM Biosciences has a pipeline of preclinical and clinical compounds and has collaborations with several pharmaceutical companies.
Company Address: 3 East Third Avenue San Mateo 94401 CA
Company Phone Number: 965-7873 Stock Exchange / Ticker: NASDAQ IGMS
|
2.4% 